AR045268A1 - Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento - Google Patents

Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento

Info

Publication number
AR045268A1
AR045268A1 ARP040102941A ARP040102941A AR045268A1 AR 045268 A1 AR045268 A1 AR 045268A1 AR P040102941 A ARP040102941 A AR P040102941A AR P040102941 A ARP040102941 A AR P040102941A AR 045268 A1 AR045268 A1 AR 045268A1
Authority
AR
Argentina
Prior art keywords
erbb2
overexpression
procedure
inhibitor
treatment
Prior art date
Application number
ARP040102941A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR045268A1 publication Critical patent/AR045268A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP040102941A 2003-08-18 2004-08-17 Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento AR045268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18

Publications (1)

Publication Number Publication Date
AR045268A1 true AR045268A1 (es) 2005-10-19

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102941A AR045268A1 (es) 2003-08-18 2004-08-17 Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento

Country Status (18)

Country Link
US (1) US20050119288A1 (enExample)
EP (1) EP1658080A1 (enExample)
JP (1) JP2007502807A (enExample)
KR (2) KR20080014144A (enExample)
CN (1) CN1838959A (enExample)
AR (1) AR045268A1 (enExample)
AU (1) AU2004264726A1 (enExample)
BR (1) BRPI0413745A (enExample)
CA (1) CA2536140A1 (enExample)
CO (1) CO5670356A2 (enExample)
IL (1) IL173127A0 (enExample)
MX (1) MXPA06001989A (enExample)
NO (1) NO20061252L (enExample)
RU (1) RU2328287C2 (enExample)
SG (1) SG135193A1 (enExample)
TW (1) TW200522966A (enExample)
WO (1) WO2005016347A1 (enExample)
ZA (1) ZA200600517B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2407473A3 (en) 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR100953246B1 (ko) * 2003-08-14 2010-04-16 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
DK1667992T3 (da) 2003-09-19 2007-04-30 Astrazeneca Ab Quinazolinderivater
RS52119B (sr) * 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
US20080194596A1 (en) * 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
WO2006138608A2 (en) * 2005-06-16 2006-12-28 Myriad Genetics, Inc. Pharmaceutical compositions and use thereof
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EA015922B1 (ru) * 2005-11-14 2011-12-30 Ариад Фармасьютикалз, Инк. ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
ATE507224T1 (de) 2005-11-15 2011-05-15 Array Biopharma Inc Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten
EP2010911A4 (en) * 2006-03-31 2009-05-13 Massachusetts Inst Technology TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS
RU2008143554A (ru) * 2006-04-05 2010-05-10 Новартис АГ (CH) Комбинации терапевтических агентов для лечения рака
JP2010509400A (ja) 2006-11-14 2010-03-25 アリアド・ファーマシューティカルズ・インコーポレイテッド 経口処方組成物
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CA2720983A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
KR20100016385A (ko) * 2007-04-10 2010-02-12 미리어드 파마슈티칼스, 인코포레이티드 뇌종양 치료방법
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
ES2417148T3 (es) 2007-06-08 2013-08-06 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
WO2013078440A2 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
EP3101115B1 (en) 2014-01-31 2020-10-21 Toppan Printing Co., Ltd. Biomolecule analysis kit and biomolecule analysis method
EP3368546A4 (en) 2015-10-28 2019-06-26 Tarveda Therapeutics, Inc. AGAINST SSTR CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE122005000053I2 (de) * 1995-03-30 2008-01-17 Pfizer Prod Inc Chinazolinderivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
HUP0301120A2 (hu) * 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
AU2002339687A1 (en) * 2001-12-12 2003-06-23 Pfizer Products Inc. Quinazoline derivatives for the treatement of abnormal cell growth
EA007412B1 (ru) * 2001-12-12 2006-10-27 Пфайзер Продактс Инк. Соли е-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил-аллил)ацетамида, их получение и их применение против рака
NZ540092A (en) * 2002-11-20 2007-06-29 Array Biopharma Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CN1729001A (zh) * 2002-12-18 2006-02-01 辉瑞产品公司 用于治疗异常细胞生长的4－苯胺基喹唑啉衍生物

Also Published As

Publication number Publication date
CA2536140A1 (en) 2005-02-24
TW200522966A (en) 2005-07-16
MXPA06001989A (es) 2006-05-17
ZA200600517B (en) 2007-02-28
CN1838959A (zh) 2006-09-27
SG135193A1 (en) 2007-09-28
NO20061252L (no) 2006-05-16
KR20060037447A (ko) 2006-05-03
BRPI0413745A (pt) 2006-10-24
JP2007502807A (ja) 2007-02-15
WO2005016347A1 (en) 2005-02-24
RU2328287C2 (ru) 2008-07-10
CO5670356A2 (es) 2006-08-31
EP1658080A1 (en) 2006-05-24
KR20080014144A (ko) 2008-02-13
IL173127A0 (en) 2006-06-11
US20050119288A1 (en) 2005-06-02
AU2004264726A1 (en) 2005-02-24
RU2006102125A (ru) 2007-09-27

Similar Documents

Publication Publication Date Title
AR045268A1 (es) Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento
WO2021243280A3 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
PH12022552739A1 (en) Fused tricyclic kras inhibitors
CR9984A (es) Método de inhibición de cinasa de tirosina cinasa 3 similar a fms
BRPI0416981A (pt) compostos para tratamento de doenças proliferativas de célula
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
UY28255A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger
WO2018102687A3 (en) Combination therapy for treating cancer
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
RU2013125042A (ru) Способ предотвращения или лечения опухоли кожи
MX2024014317A (es) Tratamientos con nirogacestat
WO2021142448A3 (en) Tgf-beta inhibitors and use thereof
NO20051170L (no) Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier
BR112022026247A2 (pt) Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
ZA202212095B (en) Il4i1 inhibitors and methods of use
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
BRPI0517075A (pt) uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr

Legal Events

Date Code Title Description
FA Abandonment or withdrawal